Author

Cheryl Dixon

Observed name: Cheryl A Dixon

Institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research

Observed institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research

OpenAlex ID: A5061991292

Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults

2024 · Heidi L Smith, Timothy J Bensman, et al. · The Journal of Infectious Diseases · 20

FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs

2021 · Elizabeth O’Shaughnessy, Yuliya Yasinskaya, et al. · Clinical Infectious Diseases · 12

Food and Drug Administration Public Workshop Summary—Development Considerations of Antifungal Drugs to Address Unmet Medical Need

2023 · Yuliya Yasinskaya, Shukal Bala, et al. · Clinical Infectious Diseases · 10

Food and Drug Administration Public Workshop Summary—Addressing Challenges in Inhaled Antifungal Drug Development

2023 · Caroline J Jjingo, Shukal Bala, et al. · Clinical Infectious Diseases · 8

Works count: 4

Citation count: 49

H-index: 4

I10-index: 3